Literature DB >> 18810763

Crohnology: a tale of time and times and inflammatory bowel diseases.

Fernando Gomollón, Javier P Gisbert, Miquel Angel Gassull.   

Abstract

Time, times and timing are key words in inflammatory bowel diseases (IBD). The leitmotif of this issue of World Journal of Gastroenterology is time. We have asked experts to review on the epidemiology of these diseases over time, the changes in innate immunity that could be present in the first time, and then the timing of key treatments. The correct time of using azathioprine, mercaptopurine, infliximab, cyclosporine and surgery are reviewed. We have chosen experts with not only great clinical expertise but also personal interest in clinical and basic investigation. Our goal in this monograph is to get an idea not only of the present but of the immediate future in some of the key management issues in IBD. To this end, we think that the authors are the most adequate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18810763      PMCID: PMC2746332          DOI: 10.3748/wjg.14.5489

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  9 in total

1.  Regional ileitis: a pathologic and clinical entity. 1932.

Authors:  B B Crohn; L Ginzburg; G D Oppenheimer
Journal:  Mt Sinai J Med       Date:  2000-05

Review 2.  [Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease].

Authors:  J P Gisbert; F Gomollón; J Maté; J M Pajares
Journal:  Gastroenterol Hepatol       Date:  2002 Jun-Jul       Impact factor: 2.102

3.  Einstein, Darwin and conventional wisdom about Crohn's disease.

Authors:  D B Sachar
Journal:  Dig Liver Dis       Date:  2005-04       Impact factor: 4.088

4.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

Authors:  Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes
Journal:  Lancet       Date:  2008-02-23       Impact factor: 79.321

Review 5.  [Common errors in the management of the seriously ill patient with inflammatory bowel disease].

Authors:  Javier P Gisbert; Fernando Gomollón
Journal:  Gastroenterol Hepatol       Date:  2007-05       Impact factor: 2.102

6.  Differential rescue of light- and food-entrainable circadian rhythms.

Authors:  Patrick M Fuller; Jun Lu; Clifford B Saper
Journal:  Science       Date:  2008-05-23       Impact factor: 47.728

Review 7.  A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Authors:  Y-F Chen; P Jobanputra; P Barton; S Jowett; S Bryan; W Clark; A Fry-Smith; A Burls
Journal:  Health Technol Assess       Date:  2006-11       Impact factor: 4.014

Review 8.  Crohn's disease: a review of current treatment with a focus on biologics.

Authors:  Julián Panés; Fernando Gomollón; Carlos Taxonera; Joaquin Hinojosa; Juan Clofent; Pilar Nos
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease.

Authors:  Edy Y Kim; John T Battaile; Anand C Patel; Yingjian You; Eugene Agapov; Mitchell H Grayson; Loralyn A Benoit; Derek E Byers; Yael Alevy; Jennifer Tucker; Suzanne Swanson; Rose Tidwell; Jeffrey W Tyner; Jeffrey D Morton; Mario Castro; Deepika Polineni; G Alexander Patterson; Reto A Schwendener; John D Allard; Gary Peltz; Michael J Holtzman
Journal:  Nat Med       Date:  2008-05-18       Impact factor: 53.440

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.